Main results
Titles and abstracts of 521 records were screened, of which we reviewed 99 from the full text. Only two studies matched our inclusion criteria. One study compared intravenous vitamin C versus no study medication for six months in 42 ESKD patients on haemodialysis who required intravenous erythropoietin (dose ≥ 450 U/kg/wk). The other included study compared high-flux dialyser versus lowflux dialyser for six months in 48 haemodialysis patients who required subcutaneous erythropoietin (dose ≥ 200 U/kg/wk). Because interventions differed, data could not be combined for quantitative meta-analysis.
Authors' conclusions
There was inadequate evidence identified to inform recommendation of any intervention to ameliorate ESA hyporesponsiveness. Adequately powered RCTs are required to establish the safety and efficacy of interventions to improve responsiveness to ESA therapy.
P L A I N L A N G U A G E S U M M A R Y

Interventions for anaemia in dialysis patients who are resistant to erythropoietin
Many people with chronic kidney disease (CKD) who are on dialysis develop anaemia (too few or poor quality red blood cells). Drugs in the erythropoiesis-stimulating family increase the production of red blood cells to resolve anaemia. Although ESAs have been highly beneficial for many, about 10% of people get either low or no benefit from treatment. Inability to control and stabilise anaemia can lead to poor rates of survival and increased risk of stroke so it is important to find effective treatment to manage anaemia in people who do not respond adequately to ESA therapy.
We searched the literature to find evidence about how best to treat people who do not benefit from ESA treatment. We found two studies: one that assessed intravenous vitamin C and another that looked at high-flux dialyser fluids as possible therapies. These studies were small (total of 90 participants) and were selective: they included haemodialysis, but not peritoneal dialysis, patients. This meant that the results of these studies could not be applied to all people with CKD on dialysis who were receiving ESA therapy. The lack of evidence meant that we could not determine or recommend an alternate treatment for people who do not respond to ESA.
More powerful and rigorous studies are needed to systematically assess all therapies that are aimed to treat people who do not respond to ESA therapy. Until such evidence is available, no therapy can be confidently recommended for this problem.
B A C K G R O U N D
Description of the condition
Erythropoiesis-stimulating agents (ESAs) are perhaps the most rigorously tested group of drugs in nephrology. Since the introduction of ESAs, there have been substantial reductions in blood transfusion requirements among patients living with chronic kidney disease (CKD) (Eschbach 1989) . A systematic review of 14 randomised controlled and uncontrolled trials in pre-dialysis CKD patients demonstrated that treatment of anaemia with ESAs improved energy levels and physical function (Gandra 2010). Unfortunately, a considerable proportion of these patients exhibited suboptimal haematologic response to ESA ( Benz 1999; Valderrabano 1996) .
There are several known causes of suboptimal response to ESA. These include deficiencies in iron, vitamin B 12 , and folate; infection, chronic inflammatory state, neoplasia, severe hyperparathyroidism, aluminium intoxication, inadequate dialysis, myelosuppressive agents, haemoglobinopathies, myelodysplasia and antibody-mediated pure red cell aplasia (Macdougall 2002) . However, after excluding these conditions it was found that about 10% of patients exhibit ESA-resistant anaemia, and these people have greatly increased rates of morbidity and mortality (Kausz 2005; Macdougall 2002; Zhang 2004) . ESA treatment used to target high haemoglobin levels in people with CKD is associated with deleterious (Phrommintikul 2007) or neutral (Palmer 2010) impacts on survival and increased risks of stroke, vascular access thrombosis and hypertension without any reduction in cardiovascular events (Palmer 2010; Phrommintikul 2007) .
Although RCTs and systematic reviews consistently show more harm than benefit associated with higher haemoglobin targets for ESA treatment (Besarab 1998 These studies also showed that patients who required higher doses of ESA experienced increased mortality at any haemoglobin level, and that patients who achieve target haemoglobin levels had better outcomes than those who did not (Badve 2011). Therefore, therapies targeting ESA resistance could be a promising treatment strategy in CKD anaemia management.
Description of the intervention
Although there is no effective treatment for patients with ESAresistant anaemia at present, a number of interventions such as Lcarnitine, ascorbic acid, oxpentifylline, androgens and statins have been investigated.
O B J E C T I V E S
This review looked at the benefits and harms of any intervention used in the treatment of ESA-resistant anaemia in people with end-stage kidney disease (ESKD) who were receiving dialysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs (studies in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at interventions for the treatment of ESA-resistant anaemia in people with ESKD were included in our review.
Types of participants
• Adults and children with ESKD (chronic kidney disease (CKD) stage 5 or pre-dialysis) or those receiving dialysis (either haemodialysis or peritoneal dialysis).
• Adults and children with ESKD receiving any type of ESA for anaemia (anaemia defined as haemoglobin < 110 g/L or as defined by the investigators).
• Evidence of ESA resistance, defined as failure to achieve or maintain target range haemoglobin/haematocrit levels in spite of appropriate ESA doses (erythropoietin ≥ 450 U/kg/wk intravenous administration or ≥ 300 U/kg/wk for subcutaneous administration or darbepoetin ≥ 1.5 µg/kg/wk) (KDOQI 2001; Locatelli 2004 ). This inclusion criterion was amended after publication of the protocol of this systematic review because only one eligible study was found. Extended inclusion criteria were studies that defined ESA-hyporesponsive state as failure to achieve or maintain target haemoglobin/haematocrit in spite of the following doses of the ESA: erythropoietin dosage ≥ 300 and ≥150 U/kg/wk for IV administration; or ≥ 200 and ≥100 U/ kg/wk for subcutaneous administration; or darbepoetin dosage ≥ 1.0 µg/kg/wk).
• All known causes of ESA-resistance (such as iron deficiency, vitamin B 12 deficiency, folate deficiency, infection, chronic inflammatory state, neoplasia, severe hyperparathyroidism, aluminium intoxication, inadequate dialysis, myelosuppressive agents, haemoglobinopathies, myelodysplasia and antibodymediated pure red cell aplasia) must have been ruled out.
• Studies performed in kidney transplant recipients were excluded.
Types of interventions
Any potential intervention used to treat ESA-resistance, such as L-carnitine, ascorbic acid, oxpentifylline, androgens, and statins, were included in this review. 
Types of outcome measures
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and abstracts of studies relevant to the review. Titles and abstracts were screened independently by three authors, who discarded studies that were not applicable. However, studies and reviews that potentially included relevant data or study information were retained initially. The same three authors independently assessed retrieved abstracts, and if necessary the full text, of these studies to determine which studies satisfied the inclusion criteria.
Data extraction and management
Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non-English language journals was to be translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancies between published versions was to be highlighted. Disagreements were resolved by consensus.
Assessment of risk of bias in included studies
The following items will be independently assessed by two authors using the risk of bias assessment tool (Higgins 2011) (see Appendix 2) .
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately prevented during the study (detection bias)?
• Participants and personnel • Outcome assessors • Were incomplete outcome data adequately addressed (attrition bias)?
• Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (all-cause mortality, cardiovascular mortality, non-fatal cardiovascular events, number of patients achieving haemoglobin/haematocrit targets, number of patients requiring hospitalisation, number of patients requiring blood transfusions, number of patients with medication-related adverse effects), results were expressed as risk ratios (RR) with 95% confidence intervals (CI). For continuous data (haemoglobin, haematocrit, iron studies, ESA dosage, iron dosage, hospitalisation days, quality of life scores, inflammatory biomarkers, biomarkers of oxidative stress), results were expressed as mean difference (MD).
Dealing with missing data
We planned that any further information required from the original author was to be requested by written correspondence, and any relevant information obtained was be included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intention-to-treat (ITT), as-treated and perprotocol (PP) population was performed.
Assessment of heterogeneity
Heterogeneity was to be analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (Higgins 2003) . I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.
Data synthesis
Data were to be pooled using the random-effects model.
R E S U L T S Description of studies
Results of the search
We identified 533 abstracts using the search strategy described (Figure 1 ). After screening titles and abstracts, 99 reports were selected for full text review. Only two studies (Attallah 2006; Ayli 2004) met our inclusion criteria, and of these, one investigated our extended inclusion criterion of ESA hyporesponsive state (Ayli 2004).
Figure 1. The PRISMA flow chart showing selection of studies
We considered inclusion of a study that applied our extended inclusion criterion of ESA-hyporesponsive state (Sezer 2002). In this study, participants in both arms received the investigational drug (vitamin C) in the first study phase (eight weeks). Nonresponders were excluded at the end of the first phase. During the second phase, remaining participants were randomised to receive either the investigational drug at a reduced frequency or no study drug for another eight weeks. Since the investigators did not define 'non-responder', and there was a strong possibility of carry over effect of vitamin C administered before randomisation, the study was excluded from this systematic review.
Included studies
Two studies met our inclusion criteria.
• Attallah 2006 enrolled 42 haemodialysis patients and compared IV vitamin C given at each dialysis session to no treatment.
• Ayli 2004 enrolled 48 haemodialysis patients and compared high-flux versus low-flux dialysis membranes
Excluded studies
We excluded 68 studies after full-text review: six were not randomised; 58 included participants who did not have ESA resistance; two included iron deficient participants who lacked true ESA resistance; and two studies did not use ESA in the control arm.
Risk of bias in included studies
Allocation Allocation concealment was unclear in both included studies ( Attallah 2006; Ayli 2004).
Blinding
It was unclear if in Attallah 2006
, an open-label study, outcome assessors were blinded. Likewise, blinding of participants, investigators or outcome assessors in Ayli 2004 was also unclear.
Incomplete outcome data
All participants were followed for the entire study period and accounted for in both studies. Attrition bias arising from incomplete outcome reporting was deemed to be low risk.
Selective reporting
Neither study reported proportions of participants in each study arm who achieved haemoglobin target levels. The risk of reporting bias in both was therefore unclear.
Other potential sources of bias
Both studies were judged to be at high risk of other potential sources of bias due to single-centre study design and exclusion of patients on peritoneal dialysis.
Effects of interventions
Treatments differed in the interventional arms of Attallah 2006 and Ayli 2004 (vitamin C and high-flux dialyser). Therefore, data were not combined and results are presented separately.
Clinical outcomes
All-cause and cardiovascular mortality
No deaths were reported in either study.
Non-fatal cardiovascular events
Attallah 2006 reported no significant difference in the risk of nonfatal cardiovascular events between study arms (Analysis 1.1: RR 0.79, 95% CI 0.20 to 3.09). Ayli 2004 did not report non-fatal cardiovascular events.
Participants achieving target haemoglobin or haematocrit
Neither study reported the proportions of participants who achieved target haemoglobin or haematocrit levels.
Requirement of blood transfusions
Attallah 2006 reported no participants included in the final analysis required blood transfusion. However, one participant from the control group was excluded from the final analysis because of the need for a blood transfusion due to a significant upper gastrointestinal bleed. Ayli 2004 did not report need for blood transfusion.
Hospitalisations
Attallah 2006 reported no significant difference in the risk of hospitalisations between the groups (Analysis 1.2: RR 0.96, 95% CI 0.56 to 1.66). Ayli 2004 did not report hospitalisations.
Medication-related adverse events
Attallah 2006 reported there were no adverse events noted in either group. Ayli 2004 did not report adverse events.
Haematology and biochemistry results
Haemoglobin
Both studies reported significantly higher haemoglobin levels in the treatment groups compared to the control groups (Analysis 2.1.1: MD 0.9 g/dL, 95% CI 0.38 to 1.42; Attallah 2006); ( Analysis 2.1.2: MD 1.9 g/dL, 95% CI 1.64 to 2.16; Ayli 2004).
Haematocrit
Attallah 2006 did not report data on participants' haematocrit levels. Ayli 2004 reported that among interventional arm participants haematocrit was significantly higher than those in the control arm (Analysis 2.2: MD 6.8%, 95% CI 5.67 to 7.93).
Transferin saturation (TSAT)
Attallah 2006 reported that TSAT was significantly higher in interventional than control arm participants (Analysis 2.3.1: MD 8.00%, 95% CI 6.22 to 9.78). There was no significant difference in TSAT between study arms reported by Ayli 2004 (Analysis 2.3.2: MD 1.30%, 95% CI -3.99 to 6.59).
Ferritin
Attallah 2006 reported that ferritin was significantly higher among interventional than control arm participants (Analysis 2.4.1: MD 8.00 ng/mL, 95% CI -85.51 to 101.51). There was no significant difference between study arms reported by Ayli 2004 (Analysis 2.4.2: MD -3.00 ng/mL, 95% CI -43.46 to 37.46).
Haemoglobin content in reticulocytes (CHr)
Attallah 2006 reported that CHr was significantly higher in interventional than control arm participants (Analysis 2.5: MD 0.90 pg, 95% CI 0.40 to 1.40). Ayli 2004 did not report CHr data.
Inflammatory biomarkers: C-reactive protein
Attallah 2006 reported C-reactive protein was significantly lower in vitamin C group compared to the control group (Analysis 2.6.1: MD -1.20 mg/dL, 95% CI -1.69 to -0.71). There was no significant difference between study arms in C-reactive protein reported by Ayli 2004 (Analysis 2.6.2: MD -0.4 mg/dL, 95% CI -3.0 to 2.2).
Markers of oxidative stress
Neither Attallah 2006 nor Ayli 2004 reported markers of oxidative stress.
ESA and intravenous iron doses ESA dose
Attallah 2006 reported ESA was significantly lower in vitamin c group compared to the control group (Analysis 3.1: MD -18 U/ kg/wk, 95% CI -35.62 to -0.38). Ayli 2004 did not report data on ESA dose.
Intravenous iron therapy dose
Attallah 2006 reported that there was no significant difference in intravenous iron therapy dose between the study arms (Analysis 3.2: MD -0.20 mg/wk, 95% CI -16.15 to 15.75). Ayli 2004 did not report on intravenous iron therapy dose.
Other outcomes Hospitalisation days
Neither Attallah 2006 nor Ayli 2004 reported numbers of hospitalisation days. 
Quality of life scores
D I S C U S S I O N
The results of this systematic review highlight the absence of adequately powered randomised controlled trials (RCT) examining the effect of various interventions to treat ESA hyporesponsiveness. We found that there was insufficient and inadequate evidence to recommend any intervention to ameliorate ESA-hyporesponsiveness.
We identified only one RCT that defined ESA-hyporesponsiveness as intravenous EPO dose ≥ 450 U/kg/wk (Attallah 2006). When inclusion criteria were extended to include subcutaneous EPO dose ≥ 200 U/kg/wk, another study, Ayli 2004, was found to be eligible for inclusion.
In relation to intravenous vitamin C therapy, Attallah 2006 demonstrated increases in haemoglobin, haemoglobin content in reticulocytes, and transferin saturation; and reductions in erythropoietin dose and C-reactive protein. Ayli 2004 reported that use of high-flux dialyser for six months was associated with improvement in haemoglobin, but there was no effect on C-reactive protein or iron studies. Both Attallah 2006 and Ayli 2004 were single-centre studies and included 42 and 48 participants respectively. The studies included only haemodialysis patients, and hence, results may not be generalisable to CKD patients not yet on dialysis, those on peritoneal dialysis, or in settings where patient populations differ.
There is no single widely accepted definition of ESA resistance. KDOQI has defined ESA resistance as failure to achieve haemoglobin 11 g/dL with ESA dose equivalent to epoetin greater than 500 IU/kg/wk (KDOQI 2006) . Publication of KDIGO anaemia guidelines is expected this year. As yet, there have been no RCTs performed explicitly in patients with ESA resistance as defined by KDOQI.
In the Normal Haematocrit Cardiac Trial, more participants in the normal haematocrit group reached the primary endpoint (composite of death and non-fatal myocardial infarction) with mean erythropoietin doses of 440 IU/kg/wk, which is lower than the KDOQI definition (Besarab 1998). In the CHOIR trial, it was reported that ESA dose > 20,000 IU/wk was associated with increased risk of death, congestive heart failure, stroke, and myocardial infarction (Szczech 2008 An emerging body of evidence indicates more harm than benefit from targeting higher haemoglobin levels with ESA therapy. Patients who needed higher doses of ESA experienced increased mortality at any haemoglobin level, and patients who achieved target haemoglobin levels had better outcomes than those who did not.
Further RCTs are needed urgently to consider the clinical impacts of therapies purported to reduce ESA resistance.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Based on two small, single-centre studies, there was inadequate evidence to recommend any intervention to ameliorate ESA-hyporesponsiveness.
Implications for research
Adequately powered multicentre RCTs involving a wide range of CKD patients receiving ESA therapy should be conducted as a priority. In addition to those on haemodialysis, future RCTs should include pre-dialysis CKD patients as well people receiving peritoneal dialysis.
Future studies should focus on true ESA responsiveness rather than a haemoglobin-targeted approach. Importantly, these studies should also include cost-effectiveness and economic analyses. -20 -10 0 10 20 
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